Company Overview of Ra Pharmaceuticals, Inc.
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Its peptide chemistry platform delivers enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. The company’s lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). It also develops Factor D inhibition for age-related macular degeneration and geographic atrophy...
87 Cambridge Park Drive
Cambridge, MA 02140
Founded in 2008
Key Executives for Ra Pharmaceuticals, Inc.
Co-Founder, Chief Executive Officer, President and Director
Chief Financial Officer and Executive Vice President of Operations
Director of Molecular Biology
Executive Director of Operations
Compensation as of Fiscal Year 2016.
Ra Pharmaceuticals, Inc. Key Developments
Ra Pharmaceuticals Seeks Acquisitions
Sep 30 16
Ra Pharmaceuticals, Inc. expects to use of the net proceeds from the offering of $86.25 million for the acquisition of businesses or technologies.
Ra Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
Sep 30 16
Ra Pharmaceuticals, Inc. filed its Annual on Sep 30, 2016 for the period ending Dec 31, 2015. In this report its auditor, Deloitte & Touche LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Ra Pharmaceuticals, Inc. Presents at Jefferies 2016 Complement Therapeutics Summit, May-03-2016 10:45 AM
Apr 26 16
Ra Pharmaceuticals, Inc. Presents at Jefferies 2016 Complement Therapeutics Summit, May-03-2016 10:45 AM. Venue: Jefferies Conference Center, New York, United States. Speakers: Douglas A. Treco, Co-Founder, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries